Immune Checkpoint Inhibitors in Cancer Therapy

Smith, 2021, Clinical cancer advances 2021: ASCO’s Report on progress against cancer, J. Clin. Oncol., 39, 1165, 10.1200/JCO.20.03420

Monkman, 2021, Understanding the tumor microenvironment for effective immunotherapy, Med. Res. Rev., 41, 1474, 10.1002/med.21765

Barbari, C., Fontaine, T., Parajuli, P., Lamichhane, N., Jakubski, S., Lamichhane, P., and Deshmukh, R.R. (2020). Immunotherapies and Combination Strategies for Immuno-Oncology. Int. J. Mol. Sci., 21.

Seidel, 2018, Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations, Front. Oncol., 8, 86, 10.3389/fonc.2018.00086

Liebl, 2019, Identification of responders to immune checkpoint therapy: Which biomarkers have the highest value?, J. Eur. Acad. Dermatol. Venereol., 33, 52, 10.1111/jdv.15992

Paucek, 2019, The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy, Trends Immunol., 40, 292, 10.1016/j.it.2019.02.002

Rizzo, 2022, PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: How can they assist drug clinical trials?, Expert Opin. Investig. Drugs, 31, 415, 10.1080/13543784.2021.1972969

Rizzo, A., Mollica, V., Santoni, M., Ricci, A.D., Rosellini, M., Marchetti, A., Montironi, R., Ardizzoni, A., and Massari, F. (2021). Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. Eur. Urol. Focus.

Rad, 2021, The Pandora’s box of novel technologies that may revolutionize lung cancer, Lung Cancer, 159, 34, 10.1016/j.lungcan.2021.06.022

Kulasinghe, 2022, Spatial Profiling Identifies Prognostic Features of Response to Adjuvant Therapy in Triple Negative Breast Cancer (TNBC), Front. Oncol., 11, 798296, 10.3389/fonc.2021.798296

Kulasinghe, 2021, Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients, Front. Oncol., 10, 3118, 10.3389/fonc.2020.607349

Monkman, J., Taheri, T., Ebrahimi Warkiani, M., O’leary, C., Ladwa, R., Richard, D., O’Byrne, K., and Kulasinghe, A. (2020). High-plex and high-throughput digital spatial profiling of Non-Small-Cell Lung Cancer (NSCLC). Cancers, 12.

Robert, 2020, A decade of immune-checkpoint inhibitors in cancer therapy, Nat. Commun., 11, 3801, 10.1038/s41467-020-17670-y

Ledford, 2011, Melanoma drug wins US approval, Nature, 471, 561, 10.1038/471561a

Johnson, 2022, Immune-checkpoint inhibitors: Long-term implications of toxicity, Nat. Rev. Clin. Oncol., 19, 254, 10.1038/s41571-022-00600-w

Cai, 2021, Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases, Front. Genet., 12, 2352, 10.3389/fgene.2021.785153

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239

Chrétien, S., Zerdes, I., Bergh, J., Matikas, A., and Foukakis, T. (2019). Beyond PD-1/PD-L1 inhibition: What the future holds for breast cancer immunotherapy. Cancers, 11.

Rolfo, 2017, Immunotherapy in NSCLC: A Promising and Revolutionary Weapon, Immunotherapy, 995, 97, 10.1007/978-3-319-53156-4_5

Wu, 2021, Therapeutic Effects of Pembrolizumab Combined with Paclitaxel and Cisplatin Chemotherapy on Advanced Non-Squamous Non-Small Cell Lung Cancer and Influencing Factors, Indian J. Pharm. Sci., 83, 120, 10.36468/pharmaceutical-sciences.757

Li, 2019, Current clinical progress of PD-1/PD-L1 immunotherapy and potential combination treatment in non–small cell lung cancer, Integr. Cancer Ther., 18, 1534735419890020, 10.1177/1534735419890020

Migden, 2018, PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma, N. Engl. J. Med., 379, 341, 10.1056/NEJMoa1805131

Mansh, 2011, Ipilimumab and cancer immunotherapy: A new hope for advanced stage melanoma, Yale J. Biol. Med., 84, 381

Shirley, 2018, Avelumab: A Review in Metastatic Merkel Cell Carcinoma, Target. Oncol., 13, 409, 10.1007/s11523-018-0571-4

Spira, 2020, Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial, Ann. Oncol., 31, 798, 10.1016/j.annonc.2020.03.287

Rocco, 2022, Chemotherapy plus single/double immunotherapy in the treatment of non-oncogene addicted advanced non-small cell lung cancer: Where do we stand and where are we going?, Expert Rev. Anticancer Ther., 22, 183, 10.1080/14737140.2022.2026772

Mazieres, 2020, Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer, J. Clin. Oncol., 38, 271, 10.1200/JCO.19.01348

Reck, 2019, Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations, Expert Rev. Respir. Med., 14, 125, 10.1080/17476348.2020.1701439

Mohsenzadegan, 2021, The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine Metab. Immune Disord.—Drug Targets, 21, 2131, 10.2174/1871530321666210310142141

Qin, 2019, Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4, Mol. Cancer, 18, 155, 10.1186/s12943-019-1091-2

Saleh, R., Toor, S.M., Khalaf, S., and Elkord, E. (2019). Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells. Vaccines, 7.

Riella, 2012, Role of the PD-1 Pathway in the Immune Response, Am. J. Transplant., 12, 2575, 10.1111/j.1600-6143.2012.04224.x

Han, 2020, PD-1/PD-L1 pathway: Current researches in cancer, Am. J. Cancer Res., 10, 727

Huang, 2021, Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis, J. Cancer, 12, 1133, 10.7150/jca.49325

Rizvi, 2015, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial, Lancet Oncol., 16, 257, 10.1016/S1470-2045(15)70054-9

Kazandjian, 2016, FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy, Oncologist, 21, 634, 10.1634/theoncologist.2015-0507

Brahmer, 2010, Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates, J. Clin. Oncol., 28, 3167, 10.1200/JCO.2009.26.7609

Paderi, A., Giorgione, R., Giommoni, E., Mela, M., Rossi, V., Doni, L., Minervini, A., Carini, M., Pillozzi, S., and Antonuzzo, L. (2021). Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 13.

Giudice, 2021, Pembrolizumab for advanced cervical cancer: Safety and efficacy, Expert Rev. Anticancer. Ther., 21, 221, 10.1080/14737140.2021.1850279

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Groisberg, 2017, Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials, J. Immunother. Cancer, 5, 100, 10.1186/s40425-017-0301-y

Inokuchi, 2019, Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma, Cancer Manag. Res., 11, 4519, 10.2147/CMAR.S167708

Vuky, 2020, Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer, J. Clin. Oncol., 38, 2658, 10.1200/JCO.19.01213

Burtness, 2019, Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study, Lancet, 394, 1915, 10.1016/S0140-6736(19)32591-7

Chen, 2021, Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer, J. Chin. Med Assoc., 84, 361, 10.1097/JCMA.0000000000000497

Argenziano, 2022, Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: An expert opinion, Ther. Adv. Med. Oncol., 14, 17588359211066272, 10.1177/17588359211066272

Stratigos, 2020, European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention, Eur. J. Cancer, 128, 60, 10.1016/j.ejca.2020.01.007

Villani, 2021, Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma, Expert Opin. Drug Saf., 21, 21, 10.1080/14740338.2022.1993819

Migden, 2020, Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial, Lancet Oncol., 21, 294, 10.1016/S1470-2045(19)30728-4

Keeping, 2021, Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma, Futur. Oncol., 17, 611, 10.2217/fon-2020-0823

Sezer, 2021, Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial, Lancet, 397, 592, 10.1016/S0140-6736(21)00228-2

Battin, 2019, Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling, Sci. Rep., 9, 11472, 10.1038/s41598-019-47910-1

Doroshow, 2021, PD-L1 as a biomarker of response to immune-checkpoint inhibitors, Nat. Rev. Clin. Oncol., 18, 345, 10.1038/s41571-021-00473-5

Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011

Dong, 1999, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, Nat. Med., 5, 1365, 10.1038/70932

Shah, 2017, Product review on the Anti-PD-L1 antibody atezolizumab, Hum. Vaccines Immunother., 14, 269, 10.1080/21645515.2017.1403694

Herbst, 2020, Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC, N. Engl. J. Med., 383, 1328, 10.1056/NEJMoa1917346

Kaplan, 2022, Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases, Curr. Oncol. Rep., 24, 343, 10.1007/s11912-022-01206-2

Inman, 2016, Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer, Clin. Cancer Res., 23, 1886, 10.1158/1078-0432.CCR-16-1417

Weinstock, 2017, Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non–Small Cell Lung Cancer, Clin. Cancer Res., 23, 4534, 10.1158/1078-0432.CCR-17-0540

Park, 2018, 136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR), J. Thorac. Oncol., 13, S79, 10.1016/S1556-0864(18)30410-6

Schmid, 2018, Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer, N. Engl. J. Med., 379, 2108, 10.1056/NEJMoa1809615

Collins, 2019, Product review: Avelumab, an anti-PD-L1 antibody, Hum. Vaccines Immunother., 15, 891, 10.1080/21645515.2018.1551671

Gaiser, 2018, PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma, Expert Rev. Clin. Pharmacol., 11, 345, 10.1080/17512433.2018.1445966

Bhatia, 2019, Avelumab in patients with previously treated metastatic Merkel cell carcinoma: Long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial, J. Immunother. Cancer, 8, e000674

Choueiri, 2018, Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): An open-label, dose-finding and dose-expansion, phase 1b trial, Lancet Oncol., 19, 451, 10.1016/S1470-2045(18)30107-4

Larkin, 2016, Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma, J. Clin. Oncol., 34, TPS4580, 10.1200/JCO.2016.34.15_suppl.TPS4580

Simeone, 2019, Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting, Futur. Oncol., 15, 3491, 10.2217/fon-2019-0348

Stewart, 2015, Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody, Cancer Immunol. Res., 3, 1052, 10.1158/2326-6066.CIR-14-0191

Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J. Clin. Oncol., 34, 3119, 10.1200/JCO.2016.67.9761

Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N. Engl. J. Med., 379, 2342, 10.1056/NEJMoa1809697

Rizvi, 2020, Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: The MYSTIC phase 3 randomized clinical trial, JAMA Oncol., 6, 661, 10.1001/jamaoncol.2020.0237

Brunet, 1987, A new member of the immunoglobulin superfamily—CTLA-4, Nature, 328, 267, 10.1038/328267a0

Rudd, 2009, CD28 and CTLA-4 coreceptor expression and signal transduction, Immunol. Rev., 229, 12, 10.1111/j.1600-065X.2009.00770.x

Linsley, 1992, Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule, Science, 257, 792, 10.1126/science.1496399

Egen, 2002, Cytotoxic T Lymphocyte Antigen-4 Accumulation in the Immunological Synapse Is Regulated by TCR Signal Strength, Immunity, 16, 23, 10.1016/S1074-7613(01)00259-X

Leach, 1996, Enhancement of Antitumor Immunity by CTLA-4 Blockade, Science, 271, 1734, 10.1126/science.271.5256.1734

Qureshi, 2011, Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4, Science, 332, 600, 10.1126/science.1202947

Gavin, 2007, Foxp3-dependent programme of regulatory T-cell differentiation, Nature, 445, 771, 10.1038/nature05543

Peggs, 2009, Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies, J. Exp. Med., 206, 1717, 10.1084/jem.20082492

Callahan, 2013, At the bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy, J. Leukoc. Biol., 94, 41, 10.1189/jlb.1212631

Mullard, 2015, FDA approves first immunotherapy combo, Nat. Rev. Drug Discov., 14, 739

Lisi, 2021, Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment, Pharmacol. Res., 175, 105997, 10.1016/j.phrs.2021.105997

Fecher, 2013, Ipilimumab and Its Toxicities: A Multidisciplinary Approach, Oncologist, 18, 733, 10.1634/theoncologist.2012-0483

Bajorin, 2021, Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma, N. Engl. J. Med., 384, 2102, 10.1056/NEJMoa2034442

Reck, 2019, Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater, J. Clin. Oncol., 37, 537, 10.1200/JCO.18.00149

Fenizia, 2018, Measuring tumor mutation burden in non-small cell lung cancer: Tissue versus liquid biopsy, Transl. Lung Cancer Res., 7, 668, 10.21037/tlcr.2018.09.23

Falvo, 2020, Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer, Cancer Res., 81, 685, 10.1158/0008-5472.CAN-20-1818

Parra, 2017, Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth, Br. J. Cancer, 116, 324, 10.1038/bjc.2016.429

Babiker, 2021, Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Oncologist, 26, e1508, 10.1002/onco.13810

Zheng, 2018, Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model, J. Immunother., 41, 361, 10.1097/CJI.0000000000000242

Hurwitz, 1999, Combination immunotherapy of B16 melanoma using anti–cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, J. Exp. Med., 190, 355, 10.1084/jem.190.3.355

Hurwitz, 2000, Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade, Cancer Res., 60, 2444

Soares, 2015, PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors, J. Immunother., 38, 1, 10.1097/CJI.0000000000000062

Derer, 2015, Immune-modulating properties of ionizing radiation: Rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors, Cancer Immunol. Immunother., 65, 779, 10.1007/s00262-015-1771-8

Stessin, 2020, Repolarized macrophages, induced by intermediate stereotactic dose radiotherapy and immune checkpoint blockade, contribute to long-term survival in glioma-bearing mice, J. Neuro-Oncol., 147, 547, 10.1007/s11060-020-03459-y

Hendriks, 2018, Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy, Transl. Lung Cancer Res., 7, 647, 10.21037/tlcr.2018.09.22

Li, 2020, Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects, Mol. Cancer, 19, 116, 10.1186/s12943-020-01234-1

Behrens, 2017, The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?, Oncoimmunology, 6, e1293215, 10.1080/2162402X.2017.1293215

Chen, 2012, Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1, Clin. Cancer Res., 18, 6580, 10.1158/1078-0432.CCR-12-1362

Ran, 2017, Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: Current status and future perspectives, Drug Des. Dev. Ther., 11, 2007, 10.2147/DDDT.S140687

Rad, 2020, The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies, Clin. Transl. Immunol., 9, e1215, 10.1002/cti2.1215

Brahmer, 2020, Immune-related adverse events of checkpoint inhibitors, Nat. Rev. Dis. Primers, 6, 38, 10.1038/s41572-020-0160-6

Bellmunt, 2017, Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma, N. Engl. J. Med., 376, 1015, 10.1056/NEJMoa1613683

Schmid, 2020, Pembrolizumab for Early Triple-Negative Breast Cancer, N. Engl. J. Med., 382, 810, 10.1056/NEJMoa1910549

Yau, 2020, Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial, JAMA Oncol., 6, e204564, 10.1001/jamaoncol.2020.4564

Sha, 2020, Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors, Cancer Discov., 10, 1808, 10.1158/2159-8290.CD-20-0522

Xiao, J., Li, W., Huang, Y., Huang, M., Li, S., Zhai, X., Zhao, J., Gao, C., Xie, W., and Qin, H. (2021). A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer, 21.

Berland, 2019, Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors, J. Thorac. Dis., 11, S71, 10.21037/jtd.2018.11.102

Shao, 2020, Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors, JAMA Netw. Open, 3, e2025109, 10.1001/jamanetworkopen.2020.25109

Marabelle, 2019, Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158, Ann. Oncol., 30, v477, 10.1093/annonc/mdz253.018

Yarchoan, 2017, Tumor Mutational Burden and Response Rate to PD-1 Inhibition, N. Engl. J. Med., 377, 2500, 10.1056/NEJMc1713444

Li, 2020, Microsatellite instability: A review of what the oncologist should know, Cancer Cell Int., 20, 16, 10.1186/s12935-019-1091-8

Randrian, V., Evrard, C., and Tougeron, D. (2021). Microsatellite Instability in Colorectal Cancers: Carcinogenesis, Neo-Antigens, Immuno-Resistance and Emerging Therapies. Cancers, 13.

Haraldsdottir, 2014, Colon and Endometrial Cancers With Mismatch Repair Deficiency Can Arise From Somatic, Rather Than Germline, Mutations, Gastroenterology, 147, 1308, 10.1053/j.gastro.2014.08.041

Luchini, 2019, ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach, Ann. Oncol., 30, 1232, 10.1093/annonc/mdz116

Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study, Lancet Oncol., 18, 1182, 10.1016/S1470-2045(17)30422-9

Dekaboruah, 2020, Human microbiome: An academic update on human body site specific surveillance and its possible role, Arch. Microbiol., 202, 2147, 10.1007/s00203-020-01931-x

Yi, 2018, The role of gut microbiota in immune checkpoint inhibitor therapy, Hepatobiliary Surg. Nutr., 7, 481, 10.21037/hbsn.2018.11.12

Xu, 2020, Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway, Front. Microbiol., 11, 814, 10.3389/fmicb.2020.00814

Liu, 2021, Gut microbiota-mediated immunomodulation in tumor, J. Exp. Clin. Cancer Res., 40, 221, 10.1186/s13046-021-01983-x

Matson, 2018, The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients, Science, 359, 104, 10.1126/science.aao3290

Zheng, 2019, Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma, J. Immunother. Cancer, 7, 193, 10.1186/s40425-019-0650-9

Vordermark, 2016, Hypoxia as a Biomarker and for Personalized Radiation Oncology, Mol. Radio-Oncol., 198, 123, 10.1007/978-3-662-49651-0_6

Waller, J., Onderdonk, B., Flood, A., Swartz, H., Shah, J., Shah, A., Aydogan, B., Halpern, H., and Hasan, Y. (2020). The clinical utility of imaging methods used to measure hypoxia in cervical cancer. Br. J. Radiol., 93.

Hu, 2021, The regulation of immune checkpoints by the hypoxic tumor microenvironment, PeerJ, 9, e11306, 10.7717/peerj.11306

Jankovic, 2006, Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix, Cytom. Part B Clin. Cytom. J. Int. Soc. Anal. Cytol., 70, 45, 10.1002/cyto.b.20086

Zandberg, 2021, Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck, J. Immunother. Cancer, 9, e002088, 10.1136/jitc-2020-002088

Lee, 2021, Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): A phase 1b/2 study, Lancet Oncol., 22, 946, 10.1016/S1470-2045(21)00241-2

Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025

Jorgovanovic, 2020, Roles of IFN-γ in tumor progression and regression: A review, Biomark. Res., 8, 49, 10.1186/s40364-020-00228-x

Castro, 2018, Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion, Front. Immunol., 9, 847, 10.3389/fimmu.2018.00847

Gocher, 2021, Interferon-γ: Teammate or opponent in the tumour microenvironment?, Nat. Rev. Immunol., 22, 158, 10.1038/s41577-021-00566-3

Zaidi, 2019, The interferon-gamma paradox in cancer, J. Interferon Cytokine Res., 39, 30, 10.1089/jir.2018.0087

Ivashkiv, 2018, IFNγ: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy, Nat. Rev. Immunol., 18, 545, 10.1038/s41577-018-0029-z

Mo, 2017, Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4, Cancer Res., 78, 436, 10.1158/0008-5472.CAN-17-1615

Dholaria, 2018, Next generation of immune checkpoint therapy in cancer: New developments and challenges, J. Hematol. Oncol., 11, 39, 10.1186/s13045-018-0582-8

Frantz, 2010, The extracellular matrix at a glance, J. Cell Sci., 123, 4195, 10.1242/jcs.023820

Gordon-Weeks, A., and Yuzhalin, A.E. (2020). Cancer Extracellular Matrix Proteins Regulate Tumour Immunity. Cancers, 12.

Bulle, 2020, Beyond just a tight fortress: Contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer, Signal Transduct. Target. Ther., 5, 249, 10.1038/s41392-020-00341-1

Huang, 2021, Extracellular matrix and its therapeutic potential for cancer treatment, Signal Transduct. Target. Ther., 6, 153, 10.1038/s41392-021-00544-0

Brassart, 2020, Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression, Front. Oncol., 10, 397, 10.3389/fonc.2020.00397

Vaquero, 2021, Author response: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment, Elife, 10, e58688, 10.7554/eLife.58688

Triebel, 1990, LAG-3, a novel lymphocyte activation gene closely related to CD4, J. Exp. Med., 171, 1393, 10.1084/jem.171.5.1393

Hodi, 2010, Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466

Helbling, 2017, Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis, Clin. Oncol., 29, 218, 10.1016/j.clon.2016.11.007

Naidoo, 2015, Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies, Ann. Oncol., 26, 2375, 10.1093/annonc/mdv383